Why Direct Funding Changes Everything
For too long, medical research has been controlled by institutions that prioritize profit over patients. We're changing that.
The Problem with Traditional Funding
The 90/10 Problem
90% of pharmaceutical R&D funding goes to conditions affecting just 10% of the global disease burden. Why? Because that's where the money is. Chronic conditions affecting smaller populations—even if they cause immense suffering—are simply ignored.
Institutional Gatekeeping
Government grants require researchers to navigate byzantine bureaucracies. Corporate funding comes with strings attached—profit potential matters more than patient need. Academic institutions take huge overhead cuts while researchers spend more time writing grants than doing research.
The Overlooked Epidemic
Thousands of conditions affect "too few" people to attract traditional funding. Post-viral syndromes, drug-induced disabilities, rare genetic conditions—these communities are told to wait for a cure that will never come because there's no financial incentive to help them.
The Direct Funding Revolution
Communities Lead
Patient communities know their needs better than any institution. They set research priorities, pool resources, and fund what matters to them. No committee approval needed.
Researchers Compete
Scientists compete on merit, not connections. The best ideas win, not the ones with institutional backing. Young researchers with fresh approaches compete equally with established labs.
Transparent Progress
Every dollar is tracked. Every milestone is reported. Communities see exactly what their money achieves. No black boxes, no bureaucratic overhead.
Speed Matters
Traditional grants take years. Corporate decisions take quarters. Suffering communities can't wait. Direct funding moves at the speed of human need.
What's Possible
Fluoroquinolone Toxicity Research
After years of being dismissed by mainstream medicine, FQ toxicity patients organized community funding efforts. Research teams are now investigating mitochondrial damage mechanisms and potential treatments.
MCAS Diagnostic Development
Mast Cell Activation Syndrome patients funded development of new diagnostic criteria and biomarkers. Research that pharma ignored is now advancing with direct community support.
Post-Finasteride Syndrome
Men suffering from persistent side effects of hair loss drugs couldn't get pharma to acknowledge the problem. Direct funding enabled independent research into endocrine disruption mechanisms.
Stop Waiting for Permission to Heal
Your community doesn't need institutional approval to fund the research you need. Take control. Fund directly. See results.